Cargando…

Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin

Patients with SARS-CoV-2 infections experience lymphopenia and inflammatory cytokine storms in the severe stage of the disease, leading to multi-organ damage. The exact pattern of immune system changes and their condition during the disease process is unclear. The available knowledge has indicated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mozafari, Negin, Azadi, Soha, Mehdi-Alamdarlou, Sanaz, Ashrafi, Hajar, Azadi, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361050/
https://www.ncbi.nlm.nih.gov/pubmed/32721805
http://dx.doi.org/10.1016/j.mehy.2020.110111
_version_ 1783559335529414656
author Mozafari, Negin
Azadi, Soha
Mehdi-Alamdarlou, Sanaz
Ashrafi, Hajar
Azadi, Amir
author_facet Mozafari, Negin
Azadi, Soha
Mehdi-Alamdarlou, Sanaz
Ashrafi, Hajar
Azadi, Amir
author_sort Mozafari, Negin
collection PubMed
description Patients with SARS-CoV-2 infections experience lymphopenia and inflammatory cytokine storms in the severe stage of the disease, leading to multi-organ damage. The exact pattern of immune system changes and their condition during the disease process is unclear. The available knowledge has indicated that the NF-kappa-B pathway, which is induced by several mediators, has a significant role in cytokine storm through the various mechanisms. Therefore, identifying the state of the immune cells and the dominant mechanisms for the production of cytokines incorporated in the cytokine storm can be a critical step in the therapeutic approach. On the other hand, some studies identified a higher risk for diabetic patients. Diabetes mellitus exhibits a close association with inflammation and increases the chance of developing COVID-19. Patients with diabetes mellitus have shown to have more virus entry, impaired immunity response, less viral elimination, and dysregulated inflammatory cytokines. The parallel analysis of COVID-19 and diabetes mellitus pathogenesis has proposed that the control of the inflammation through the interfering with the critical points of major signaling pathways may provide the new therapeutic approaches. In recent years, the role of Dipeptidyl Peptidase 4 (DPP4) in chronic inflammation has been proved. Numerous immune cells express the DPP4 protein. DPP4 regulates antibody production, cytokine secretion, and immunoglobulin class switching. DPP4 inhibitors like sitagliptin reduce inflammation intensity in different states. Following the accumulating data, we hypothesize that sitagliptin might reduce COVID-19 severity. Sitagliptin, an available DPP4 inhibitor drug, showed multidimensional anti-inflammatory effects among diabetic patients. It reduces the inflammation mostly by affecting on NF-kappa-B signaling pathway. Under the fact that inflammatory mediators are active in individuals with COVID-19, blocking the predominant pathway could be helpful.
format Online
Article
Text
id pubmed-7361050
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73610502020-07-15 Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin Mozafari, Negin Azadi, Soha Mehdi-Alamdarlou, Sanaz Ashrafi, Hajar Azadi, Amir Med Hypotheses Article Patients with SARS-CoV-2 infections experience lymphopenia and inflammatory cytokine storms in the severe stage of the disease, leading to multi-organ damage. The exact pattern of immune system changes and their condition during the disease process is unclear. The available knowledge has indicated that the NF-kappa-B pathway, which is induced by several mediators, has a significant role in cytokine storm through the various mechanisms. Therefore, identifying the state of the immune cells and the dominant mechanisms for the production of cytokines incorporated in the cytokine storm can be a critical step in the therapeutic approach. On the other hand, some studies identified a higher risk for diabetic patients. Diabetes mellitus exhibits a close association with inflammation and increases the chance of developing COVID-19. Patients with diabetes mellitus have shown to have more virus entry, impaired immunity response, less viral elimination, and dysregulated inflammatory cytokines. The parallel analysis of COVID-19 and diabetes mellitus pathogenesis has proposed that the control of the inflammation through the interfering with the critical points of major signaling pathways may provide the new therapeutic approaches. In recent years, the role of Dipeptidyl Peptidase 4 (DPP4) in chronic inflammation has been proved. Numerous immune cells express the DPP4 protein. DPP4 regulates antibody production, cytokine secretion, and immunoglobulin class switching. DPP4 inhibitors like sitagliptin reduce inflammation intensity in different states. Following the accumulating data, we hypothesize that sitagliptin might reduce COVID-19 severity. Sitagliptin, an available DPP4 inhibitor drug, showed multidimensional anti-inflammatory effects among diabetic patients. It reduces the inflammation mostly by affecting on NF-kappa-B signaling pathway. Under the fact that inflammatory mediators are active in individuals with COVID-19, blocking the predominant pathway could be helpful. Elsevier Ltd. 2020-10 2020-07-15 /pmc/articles/PMC7361050/ /pubmed/32721805 http://dx.doi.org/10.1016/j.mehy.2020.110111 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mozafari, Negin
Azadi, Soha
Mehdi-Alamdarlou, Sanaz
Ashrafi, Hajar
Azadi, Amir
Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
title Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
title_full Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
title_fullStr Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
title_full_unstemmed Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
title_short Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
title_sort inflammation: a bridge between diabetes and covid-19, and possible management with sitagliptin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361050/
https://www.ncbi.nlm.nih.gov/pubmed/32721805
http://dx.doi.org/10.1016/j.mehy.2020.110111
work_keys_str_mv AT mozafarinegin inflammationabridgebetweendiabetesandcovid19andpossiblemanagementwithsitagliptin
AT azadisoha inflammationabridgebetweendiabetesandcovid19andpossiblemanagementwithsitagliptin
AT mehdialamdarlousanaz inflammationabridgebetweendiabetesandcovid19andpossiblemanagementwithsitagliptin
AT ashrafihajar inflammationabridgebetweendiabetesandcovid19andpossiblemanagementwithsitagliptin
AT azadiamir inflammationabridgebetweendiabetesandcovid19andpossiblemanagementwithsitagliptin